VJRegenMed is committed to improving our service to you

Share this video  

VJRegenMed is committed to improving our service to you

EBMT 2020 | Selecting DLBCL patients for CAR T-cell therapies

Anna Sureda • 1 Sep 2020
EBMT 2020
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma CAR-T
Real-World Data Treatment

Anna Sureda, MD, PhD, Catalan Institute of Oncology, Barcelona, Spain, discusses how patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) are selected for CAR T-cell therapies and the associated challenges. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

More from Anna Sureda

2:13
CAR-T in DLBCL: 4-year follow-up data from ZUMA-1
Anna Sureda • 9 Feb 2021
1:08
Highlights from the 3rd European CAR T-cell Meeting
Anna Sureda • 9 Feb 2021
2:15
The future of CAR T-cell therapy in lymphoma
Anna Sureda • 9 Feb 2021

Related Videos

3:02
Phase I study of rapcabtagene autoleucel in patients with R/R DLBCL
Nirav Shah • 15 Feb 2023
3:19
Safety and efficacy of LV20.19 CAR-T therapy in Richter's transformation and R/R MCL
Nirav Shah • 15 Feb 2023
2:17
The importance of managing hematologic toxicity associated with CAR-T therapy
Marion Subklewe • 10 Feb 2023
1:23
CARBON trial: investigating CTX110 allogeneic CRISPR-Cas9–engineered CAR-Ts in R/R LBCL
Constantine Tam • 12 Dec 2022
The content of VJRegenMed is intended for healthcare professionals